Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17670466 | 0.85 | ERN1 (0.45) | ERN1MAPTFYNCDK2LRRK2 | |
| SCHEMBL17680436 | 0.79 | ERN1 (0.46) | ERN1MAPTMAOAMAOBCREBBP | |
| SCHEMBL19175137 | 0.73 | ERN1 (0.44) | ERN1MAPTCREBBPLRRK2 | |
| SCHEMBL15508177 | 0.73 | FYN (0.52) | ERN1FYNCREBBPALKCDK2 | |
| SCHEMBL17670401 | 0.69 | ERN1 (0.50) | ERN1MAPTFYNALKCCNT1 | |
| SCHEMBL22652108 | 0.69 | ERN1 (0.52) | ERN1MAPTCDK2BRD4 | |
| SCHEMBL16134054 | 0.69 | MAPT (0.58) | ERN1MAPTBRD4 | |
| SCHEMBL17683760 | 0.68 | ERN1 (0.44) | ERN1FYNLRRK2BRD4 | |
| SCHEMBL6374348 | 0.68 | ALDH1A1 (0.54) | ERN1BRD4 | |
| SCHEMBL17785856 | 0.68 | ALDH1A1 (0.47) | ERN1MAPTALKCCNT1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | ERN1 582/4885MAPT 1871/4885FYN 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.